This specialized case study explores Kymanox’s approach to FDA discipline review resolution and Human Factors (HF) regulatory strategy through comprehensive validation oversight and submission optimization. Our team of Subject Matter Experts (SMEs) collaborated closely with project stakeholders to implement measurable improvements across Use-Related Risk Analysis (URRA), User Interface (UI) design, validation study execution, and Human Factors Engineering/Usability Engineering (HFE/UE) documentation for groundbreaking transdermal patch delivery systems.
CHALLENGE
SOLUTION
RESULTS
- Pharmaceutical client required efficient management and resolution of FDA Discipline Review Letter addressing HF concerns for transdermal patch product.
- Comprehensive HF regulatory strategy development needed to ensure successful FDA approval for innovative drug delivery route.
- Expert oversight required for HF validation study partner selection and execution ensuring regulatory compliance and data quality.
- Strategy user interface optimization and manufacturing direction essential to address FDA concerns while maintaining product feasibility.
- Conducted comprehensive review of existing HF documentation including URRA, Instructions for Use (IFU), completed HF study data, and root cause analysis.
- Provided expert recommendations on strategic next steps addressing FDA discipline review concerns and strengthening regulatory position.
- Reviewed and evaluated proposed UI changes, providing strategic manufacturing direction ensuring feasibility and compliance.
- Supported HF study partner selection process and oversaw validation study execution including protocol review, study report evaluation, and use-related risk documentation.
- Updated HFE/UE summary report for final submission ensuring comprehensive regulatory compliance.
- Successfully achieved FDA approval in March 2022 as first FDA-approved product available for selected route of administration, establishing market leadership.
- Efficiently managed FDA discipline review response process minimizing delays and maintaining cricial project timelines.
- Delivered robust validation evidence and strengthened HF documentation satisfying stringent FDA regulatory requirements for novel delivery system.